Short communication · 2016
Conference abstractPublished 25 Aug 2015
Involvement of genetics in poor outcomes in anticoagulation therapy
Newcastle University, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Warfarin is commonly prescribed for the treatment and prevention of thromboembolic disorders. Anticoagulation response to warfarin during the initiation of therapy is variable. This is mainly due to the drug’s narrow therapeutic window and the wide inter-individual variability in warfarin dose requirement which makes the prediction of an accurate dose for individual patients difficult despite the use of standard induction regimens and frequent INR monitoring. As a result, some patients who are sensitive to warfarin are at increased risk of bleeding due to over-dosing whereas some are at increased risk of thrombosis due to underdosing. Approximately half of the variability in warfarin dose requirement is explained by patient age, body size and CYP2C9 and VKORC1 genes. A personalized approach to warfarin dosing using genetic information has the potential to improve the safety and efficacy of anticoagulation therapy. The author will be presenting the results of prospective trials exploring the potential benefits of pharmacogenetics-based therapy and the potential for future implementation of pharmacogenetics-guided therapy in the clinic setting.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Case report · 31 Dec 2024
Optimizing Anticoagulant Therapy in Atrial Fibrillation: A Comparative Analysis of Warfarin and Direct Oral Anticoagulants
Perspective · 30 Dec 2025
Enzyme Induction and Its Influence on Drug Therapy Outcomes
Conference abstract
Under-reporting of adverse drug reactions: A problem that also involves medicines subject to additional monitoring; preliminary data from a single-centre experience on novel oral anticoagulants
Research article · 21 May 2021
In-Hospital Clinical Outcomes of Covid-19 Patients Treated with Oral Anticoagulants.
More from this journal
The newest in Journal of Drug Metabolism & Toxicology.
Short communication · 30 Dec 2025
Liver Drug Metabolism Mechanisms Challenges and Future Perspectives
Opinion · 30 Dec 2025
Hepatic metabolism forms the foundation of drug disposition in the human body
Opinion · 30 Dec 2025
Biomarkers of Toxicity for Monitoring Adverse Drug Reactions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Drug Metabolism & Toxicology
- SubjectDiabetes & Endocrinology
- SubjectPharmaceutical Sciences
- SubjectToxicology
- BylineArticles whose byline prints “Farhad Kamali”

